The US Supreme Court on Monday, October 16, agreed to decide whether American Express is violating federal antitrust law by forbidding merchants that accept its credit cards from encouraging customers to use rival cards that charge lower fees.
The justices will hear an appeal by 11 states led by Ohio that sued American Express of a lower court ruling last year that endorsed the legality of the company’s “anti-steering” provisions in contracts with merchants.
Merchants annually pay more than US$50 billion in so-called swipe fees to process credit card transactions, and these fees can be passed along to customers through higher prices.
New York-based American Express charges merchants higher fees relative to the other credit card networks, and generates more revenue, according to the states’ legal papers. The company accounts for about 26% of all US credit card transactions.
As a result of advertising campaigns in the 1980s by competitors Visa and MasterCard, aimed at convincing merchants and consumers to use cards with cheaper fees, American Express tightened contract provisions with merchants to stop what it called discrimination against its cards.
The company said in a court filing that lower fees paid by merchants would mean fewer benefits for cardholders.
The Obama administration and 17 US states sued American Express in 2010 alleging that the company’s anti-steering contract requirement obstructs merchants from using competition to try to keep credit card fees from increasing.
A trial court agreed, finding that the rules kept lower cost networks out of the field and led to higher prices for merchants and consumers. In September 2016, the 2nd US Circuit Court of Appeals in New York overturned that ruling.
Full Content: Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas